---
title: "GH Reports Primary Endpoint Met In Phase 2a For GH001 In Treating Post-Partum Depression"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288847360.md"
description: "GH Research PLC announced that its lead candidate GH001 met the primary endpoint in a Phase 2a trial for post-partum depression. The study showed a mean MADRS reduction of 35.4 points and 100% patient remission within two hours. Results support advancing to larger trials. Despite positive clinical data, GHRS stock fell 4.83% to $23.25."
datetime: "2026-06-05T10:35:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288847360.md)
  - [en](https://longbridge.com/en/news/288847360.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288847360.md)
generator: "portal-rs"
---

# GH Reports Primary Endpoint Met In Phase 2a For GH001 In Treating Post-Partum Depression

(RTTNews) - GH Research PLC (GHRS), a clinical-stage biopharmaceutical company, on Thursday announced Phase 2a results for GH001 in treating post-partum depression (PPD). Results were published in The Journal of Clinical Psychiatry.

The company's lead candidate GH001 contains mebufotenin formulated via a proprietary inhalation approach. 

The Phase 2b GH001-TRD-201 trial was a single-arm, open-label study with 10 enrolled PPD patients. The primary endpoint was set at a reduction in depression measured by the Montgomery-Asberg Depression Rating Scale (MADRS).

Results indicate that the primary endpoint was met, with patients showing a mean MADRS reduction of 35.4 points from the baseline to Day 8. Additionally, 100% of patients achieved remission (MADRS less than 10) within two hours of dosing. An improvement in maternal functioning was also noted, with a mean 34.1-point increase on the Barkin Index of Maternal Functioning by Day 8. The drug was found to be well-tolerated. 

The company stated that the results supported further investigation of inhaled mebufotenin in larger, randomized, placebo-controlled trials in PPD. 

GH001 is being advanced in the studies for treatment-resistant depression (TRD).

GHRS closed Thursday at $23.25, down 4.83%. 

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [GHRS.US](https://longbridge.com/en/quote/GHRS.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [GH Research publishes corporate presentation on ultra-rapid, durable remission data for TRD treatment GH001](https://longbridge.com/en/news/295098135.md)
- [Filament Health ships psilocybin candidate PEX010 for University of Washington Phase 2a cancer anxiety, depression trial](https://longbridge.com/en/news/296906129.md)
- [Endovia Health opens FDA INAD file for CannEpil veterinary program](https://longbridge.com/en/news/296915045.md)
- [GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy](https://longbridge.com/en/news/296748151.md)
- [Bio-Works wins SEK 2.8 million order from new US mRNA medicine developer](https://longbridge.com/en/news/296870494.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**